_(3).png)
_(4).png){kind=logo}
Loading Shopping Cart Items...
FREE FOR MEMBERS!
Description: Lyme disease is the most important tick-borne disease in Canada. On-going range expansion of its principal vector, the blacklegged tick, means that the burden of Lyme disease is likely to increase over time. Serological testing has been the primary tool to provide laboratory evidence of exposure to Borrelia burgdorferi, the agent of Lyme disease. Testing currently involves a two-step approach [an Enzyme Immunoassay (EIA) for screening followed by immunoblots (IgM and/or IgG) on reactive samples]. Use of a modified two-tiered testing approach (two EIAs) for Lyme disease is under consideration and plans for validation/implementation of this new algorithm will be described.
Start date: Upon registration
Completion: Up to 52 weeks
At the end of this webinar you will be able to:
Speaker: Robbin Lindsay, Research Scientist, Public Health Agency of Canada
Robbin Lindsay received his Bachelor’s degree from the University of Winnipeg in 1986, a Master’s degree from the University of Manitoba in 1989, and his PhD from the University of Guelph in 1995. He currently is employed with the Public Health Agency of Canada at the National Microbiology Laboratory in the Zoonotic Disease and Special Pathogens section. The focus of his work is laboratory and field-based surveillance for various zoonotic disease agents including tick-borne infections like Lyme disease and mosquito-borne infections such as West Nile virus and Zika. Today’s talk will be on “what’s new with Lyme disease diagnostic testing in Canada”.
Recorded: May 13, 2021
PEP hours: 1.0
CPS credits: 0
*Note: PEP hours and/or CPS credits will only be awarded upon successful completion of the quiz.
Loading Shopping Cart Items...